EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) 21. September 2017, section EUDA news
10. March 2026 From essential medicine to illicit commodity: new EU report reveals how ketamine diversion is fuelling the illicit market in Europe Ketamine produced legitimately outside the EU to make medicines is increasingly finding its way onto Europe’s illicit drug...
